Prevalence of hearing loss in newborns of mothers who had malaria and were treated with antimalaric drugs in pregnancy

Aurélio, Fernanda Soares; Dutra, Ísis Pereira; Silva, Virgínia Braz da; Sampaio, André Luiz Lopes; Oliveira, Carlos Augusto Costa Pires de

doi:10.5935/0946-5448.20140010

Cited by 9 publications

(32 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 9 There are also case reports of hearing loss in newborns of mothers who had malaria and used chloroquine during pregnancy. 8 11 The occurrence of malaria in this period and its treatment, especially in the third trimester, can have implications for fetal or neonatal development. 31 …”

Section: Discussionmentioning

confidence: 99%

“…These drugs accumulate and fix selectively in melanocytes of cochlear sensory hair cells, resulting in variable injuries that can be irreparable. 3 8 There are reports about children with systemic lupus erythematosus who developed ototoxicity soon after the therapy with hydroxychloroquine was initiated. 9 There are also cases reported in the literature, since 1968, of hearing loss in newborns of mothers who had malaria and used chloroquine during pregnancy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Chloroquine and COVID-19: Should We Care about Ototoxicity?

Monteiro

Nascimento

Brito

et al. 2020

Int Arch Otorhinolaryngol

View full text Add to dashboard Cite

Introduction Severe acute respiratory syndrome coronavirus 2 was first described in December 2019 in China leading to a Public Health Emergency of International Concern. It was named by the World Health Organization as Coronavirus Disease 2019 (COVID-19), and it garnered unprecedented attention from public health researchers around the world, and studies analyzing chloroquine and hydroxychloroquine as a possible therapy have arisen in the last 2 months. Objective To review the literature and describe updated facts about the ototoxicity of chloroquine and hydroxychloroquine, an important side effect that can be present in patients with COVID-19 treated with these drugs. Data Synthesis The most typical treatment regimen is 5 days of hydroxychloroquine at daily doses of 400 to 600 mg. There is no randomized clinical trial that can prove so far the efficacy of this medication, and few studies have evaluated adverse events potentially linked to their use in patients with COVID-19. While there is no concrete evidence on the incidence of ototoxicity using chloroquine in the short term, we need to consider that, as a pandemic disease, millions of patients with COVID-19 may receive this treatment, and ototoxicity can be a possible adverse event. Conclusion Despite the urgent global situation caused by the COVID-19, the risk of irreversible hearing loss may outweigh the unproven benefit of using hydroxychloroquine or chloroquine, especially in patients with mild forms of COVID-19, who may be cured with supportive treatment. The potential hearing loss that can be caused by these medications may advise against their use in COVID-19 patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Chloroquine and COVID-19: Should We Care about Ototoxicity?

Monteiro

Nascimento

Brito

et al. 2020

Int Arch Otorhinolaryngol

View full text Add to dashboard Cite

show abstract

“…45 Malaria during pregnancy, especially in the last 3 months and the use of antimalarial drugs, including chloroquine, chloroquine combined with quinine, and quinine combined with Fansidar, leads to cochlear damage, generally affecting high frequency hearing. 46 In addition, macrolides, chloramphenicols, vancomycin, polymyxins, and acetyl salicylic acid have been reported to cause HL. 37 Other Adequate oxygenation is necessary for the cochlea to maintain normal function; hypoxia and HL are closely related.…”

Section: Ototoxic Drugsmentioning

confidence: 99%

Change to Hearing Loss–Related Risks and Screening in Preterm Infants

2020

View full text Add to dashboard Cite

Hearing loss is one of the most common congenital defects in infancy; it increases speech and language delays and adversely affects academic achievement and socialemotional development. The risk of hearing loss in premature infants is higher than that in normal newborns, and because of the fragility of the auditory nervous system, it is more vulnerable to different risk factors. The hearing screening guidelines in current use were proposed by the American Academy of Pediatrics and updated in 2007, but there are no uniform guidelines for hearing screening in preterm infants. This review focuses on the risk factors related to hearing loss in premature infants, hearing screening strategies, and reasons for failure. The aim is to provide a more comprehensive understanding of hearing development in preterm infants to achieve early detection and early intervention. At the same time, attention should be paid to delayed auditory maturation in preterm infants to avoid excessive intervention. Key Points

show abstract

“…Pesquisa realizada no programa de TAN do hospital supracitado evidenciou que os neonatos de mães tratadas para a malária na gravidez apresentam prevalência de falha na TAN de 6,7% e 5.64 vezes mais chance de falhar do que os recémnascidos (RN) de mães não tratadas (30), sendo constatado em outro estudo, realizado no mesmo programa, 3% de perda auditiva em RN de mães tratadas para malária gestacional (31).…”

Section: Introductionunclassified

“…Porém, as poucas publicações existentes (29)(30)(31)(32) Na 23ª semana, a cóclea atinge a sua total dimensão com espaços perióticos bem definidos e formados (33). Sendo assim, o desenvolvimento anatômico e fisiológico do sistema auditivo periférico está completo no quinto mês de vida intra-uterina, sendo possível e passível estudá-lo nos períodos pré-natal, neonatal e pós-natal (34).…”

Section: Introductionunclassified

Triagem auditiva em neonatos de mães que utilizaram antimaláricos na gestação sem outros indicadores de risco

Patatt¹

View full text Add to dashboard Cite

Prevalence of hearing loss in newborns of mothers who had malaria and were treated with antimalaric drugs in pregnancy

Cited by 9 publications

References 24 publications

Chloroquine and COVID-19: Should We Care about Ototoxicity?

Chloroquine and COVID-19: Should We Care about Ototoxicity?

Change to Hearing Loss–Related Risks and Screening in Preterm Infants

Triagem auditiva em neonatos de mães que utilizaram antimaláricos na gestação sem outros indicadores de risco

Contact Info

Product

Resources

About